Garsorasib In KRAS G12C Mutant Locally Advanced and Metastatic NSCLC

NCT ID: NCT07294261

Last Updated: 2025-12-19

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: PHASE2
• Total Enrollment: 69 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-12-23
• Study Completion Date: 2028-12-30

Brief Summary

This study is aimed to evaluate the efficacy and safety of the Garsorasib combination therapy in KRAS G12C mutant locally advanced and metastatic NSCLC

Conditions

Local Advanced or Metastatic NSCLC

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Cohort1: PD-L1≧1%, Garsorasib+Benmelstobart+Anlotinib

Histologically confirmed KRAS G12C mutant and PD-L1≧1% local advanced or metastatic NSCLC, at least 1 measurable lesion (RECIST 1.1) ECOG 0-1, treatment naive patients, first step enroll 6-9 patients, 3+3 dose escalation study start with Garsorasib 400mg qd. Patients randomised to Cohort1 or Cohort2. Garsorasib RP2D QD D1-21, Benmelstobart 1200 mg IV D1, q21d, Anlotinib 8mg QD, D1-14,q21d. N1=20 participants.

Group Type: EXPERIMENTAL

Garsorasib, Benmelstobart, Anlotinib

Intervention Type: DRUG

Cohort1: Garsorasib RP2D QD D1-21, Benmelstobart 1200 mg IV D1, q21d, Anlotinib 8mg QD, D1-14,q21d. N1=20 participants.

Cohort2: PD-L1≧1%, Benmelstobart+Anlotinib

Histologically confirmed KRAS G12C mutant and PD-L1≧1% local advanced or metastatic NSCLC, at least 1 measurable lesion (RECIST 1.1) ECOG 0-1, treatment naive patients.

Group Type: EXPERIMENTAL

Benmelstobart, Anlotinib

Intervention Type: DRUG

Benmelstobart 1200 mg IV D1, q21d, Anlotinib 8mg QD, D1-14,q21d. N2=20 participants.

Cohort3: PD-L1<1%, Garsorasib+Cetuximab Beta Injection

Histologically confirmed KRAS G12C mutant and PD-L1\<1% local advanced or metastatic NSCLC, at least 1 measurable lesion (RECIST 1.1) ECOG 0-1, treatment naive patients

Group Type: EXPERIMENTAL

Garsorasib, Cetuximab Beta Injection

Intervention Type: DRUG

Garsorasib 600mg BID, D1, q14d, Cetuximab Beta Injection 500mg/㎡ IV, q14d. N3=20 participants

Interventions

Garsorasib, Benmelstobart, Anlotinib

Cohort1: Garsorasib RP2D QD D1-21, Benmelstobart 1200 mg IV D1, q21d, Anlotinib 8mg QD, D1-14,q21d. N1=20 participants.

Intervention Type: DRUG

Benmelstobart, Anlotinib

Benmelstobart 1200 mg IV D1, q21d, Anlotinib 8mg QD, D1-14,q21d. N2=20 participants.

Intervention Type: DRUG

Garsorasib, Cetuximab Beta Injection

Garsorasib 600mg BID, D1, q14d, Cetuximab Beta Injection 500mg/㎡ IV, q14d. N3=20 participants

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• 1. A written informed consent form should be signed prior to any study-related procedures 2. Male or female, aged 18 or above. 3.Histologically confirmed IIIB-IV NSCLC. 4.Subjects have not received systemic treatment for locally advanced or metastatic non-small cell lung cancer. 5.The patients should be confirmed with KRAS G12C mutation and provide PD-L1 test result. 6.At least 1 measurable lesion (RECIST 1.1 criteria). 7.ECOG 0-1. 8. Good organ function includes:
• Neutrophil count≥1.5×109/L,
• Platelet count≥90×109/L,
• Hemoglobin≥90g/L
• Serum creatinine≤1.5×upper limit of normal (ULN), creatinine clearance≥50 mL/min (Cockcroft-Gault formula)
• Total bilirubin≤1.5×ULN
• AST and ALT≤2.5×ULN; for patients with liver metastasis, AST and ALT≤5×ULN, the investigator should determine whether they are enrolled
• Normal coagulation function: INR and PT≤1.5×ULN ,APTT≤1.5×ULN
• Urinary protein in routine urinalysis is less than 2+, or 24-hour urinary protein quantification is < 1 g.

9. Life expectancy is at least 3 months; 10.Negative pregnancy test at enrollment. Male or female subjects should commit to take adequate and effective contraceptive measures or abstain from sexual for the duration of study participation and within 3 months after the last dose of the study drug

Exclusion Criteria

• 1.Patients received anti-tumor drug treatment or investigational drug treatment 3 years ago.2.Non-Small Cell Lung Cancer (NSCLC) with a history of other actionable driver gene mutations for which standard treatment drugs are available (e.g., EGFR, ALK, BRAF(V600E), HER-2, MET(exon14), ROS1, RET, or NTRK1/2/3, etc.) 3.Other active malignant tumors requiring concurrent treatment 4.Patients with active brain metastasis, cancerous meningitis, spinal cord compression, or with brain or pia mater diseases detected by CT or MRI at screening time (patients with stable symptoms and complete treatment 14 days before enrollment may be admitted to the group, but no symptoms of cerebral hemorrhage should be confirmed by craniocerebral MRI, CT or venography evaluation).5.Serious cardiovascular history:
• NYHA (New York Heart Association) Class 3 and 4 congestive heart failure
• Arrhythmia requiring therapeutic intervention
• Thrombotic or embolic event within the past 6 months, e.g., cerebrovascular accident (including transient ischemic attack), and pulmonary embolism
• LVEF<50%
• Subjects with a prolonged QT interval corrected by the Fridericia formula (QTcF) at rest, where the QTcF measured by electrocardiogram (ECG) is > 470 ms in females or > 450 ms in males; or subjects with risk factors for torsades de pointes (TdP), such as hypokalemia deemed clinically significant by the investigator, a family history of long QT syndrome, or a family history of arrhythmias (e.g., pre-excitation syndrome).
• Uncontrollable hypertension (systolic blood pressure ≥ 140 mmHg, or diastolic blood pressure ≥ 90 mmHg, despite using the optimal medical treatment; 6.Subjects with arterial/venous thrombotic events occurring within 6 months, such as cerebrovascular accidents (including transient ischemic attacks), deep vein thrombosis, and pulmonary embolism; or subjects with hypertensive crisis or hypertensive encephalopathy.7.Subjects with a previous history of epilepsy.8.Presence of superior vena cava syndrome.9.Active non-infectious pneumonia with interstitial changes such as interstitial lung disease, radiation pneumonitis, or immune-related pneumonitis during the screening period; active pulmonary tuberculosis; pneumoconiosis; other types of pneumonia graded ≥ Grade 2; or severe impairment of pulmonary function confirmed by pulmonary function tests (FEV1, DLCO, or DLCO/VA < 40% of the predicted value).10.Presence of severe bone damage caused by bone metastases, or a risk of such damage occurring after enrollment-for example, pathological fractures of weight-bearing bones that have occurred within 6 months or may occur after enrollment, extensive bone metastases, or spinal cord compression; or uncontrolled pain related to bone metastases.11.Active or uncontrolled severe infection (≥ CTCAE Grade 2 infection) or unexplained fever > 38.5°C. 12.Third-space fluid accumulation (including pleural effusion, ascites, or pericardial effusion) that is poorly controlled clinically or requires local symptomatic management such as percutaneous drainage. 13.Imaging (CT or MRI) shows that the tumor invades large blood vessels or has an unclear boundary with large blood vessels.14.Subjects with evidence of or a history of bleeding tendency within 2 months prior to the first dose, regardless of severity; subjects with a history of hemoptysis (> 2.5 ml/day) within 2 weeks prior to the first dose, or with unhealed wounds, ulcers, or fractures.15.Known gastrointestinal (GI) dysfunction or gastrointestinal (GI) diseases that may significantly affect the absorption or metabolism of oral medications.16.Have received a live-attenuated preventive vaccine within 4 weeks prior to the first dose.17.Subjects who have experienced severe hypersensitivity reactions after receiving other monoclonal antibody drugs.18.Active autoimmune diseases requiring systemic treatment that occurred within 2 years. 19.Immunodeficiency, or ongoing systemic glucocorticoid treatment, or any other form of immunosuppressive therapy. 20.Active viral infections such as HIV, hepatitis B, hepatitis C, etc. 21.Active syphilis.22.Subjects with renal failure requiring hemodialysis or peritoneal dialysis. 23.Uncontrolled diabetes, FBG>10mmol/L. 24.Received organ transplantation or planned to undergo organ transplantation. 25.Undergone major surgical treatment or significant traumatic injury within 4 weeks. 26.Received palliative radiotherapy for local lesions within 2 weeks. 27.Toxicity of any previous therapy have not recovered to ≤ CTCAE Grade 1 or baseline 28.Pregnant or breeding women. 29.Severe psychiatric or psychological disorders, a history of substance abuse, or a history of severe alcoholism. 30.Allergy to the investigational medicinal product or any of its excipients. 31. The patient is not appropriate for the study In the opinion of the investigator.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

INDUSTRY

Sponsor Role: collaborator

Sun Yat-sen University

OTHER

Sponsor Role: lead

Responsible Party

Li Zhang, MD

Li zhang, DOCTOR SUN YAT-SEN UNVERISITY CANCER CENTER

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

Sun Yat-sen University

Guangzhou, Guangdong, China

Countries

China

Central Contacts

Li Zhang, Doctor

Role: CONTACT

Phone: +8613902282893

Email: zhangli@sysucc.org.cn

Wenfeng Fang, Doctor

Role: CONTACT

Phone: +8615322302066,

Email: fangwf@sysucc.org.cn

Facility Contacts

Li Zhang, Doctor

Role: primary

Wenfeng Fang, Doctor

Role: backup

References

Yaeger R, Weiss J, Pelster MS, Spira AI, Barve M, Ou SI, Leal TA, Bekaii-Saab TS, Paweletz CP, Heavey GA, Christensen JG, Velastegui K, Kheoh T, Der-Torossian H, Klempner SJ. Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C. N Engl J Med. 2023 Jan 5;388(1):44-54. doi: 10.1056/NEJMoa2212419. Epub 2022 Dec 21.

Reference Type: RESULT

PMID: 36546659 (View on PubMed)

Huang L, Guo Z, Wang F, Fu L. KRAS mutation: from undruggable to druggable in cancer. Signal Transduct Target Ther. 2021 Nov 15;6(1):386. doi: 10.1038/s41392-021-00780-4.

Reference Type: RESULT

PMID: 34776511 (View on PubMed)

Molina-Arcas M, Downward J. Exploiting the therapeutic implications of KRAS inhibition on tumor immunity. Cancer Cell. 2024 Mar 11;42(3):338-357. doi: 10.1016/j.ccell.2024.02.012.

Reference Type: RESULT

PMID: 38471457 (View on PubMed)

Other Identifiers

B2025-331-01

Identifier Type: -

Identifier Source: org_study_id